Moderately potent NMDA and AMPA/kainate receptor antagonist. (S)-3-Carboxy-4-hydroxyphenylglycine (Cat. No. 0329) also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in 1eq. NaOH|
Preparing Stock Solutions
The following data is based on the product molecular weight 211.17. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.74 mL||23.68 mL||47.36 mL|
|5 mM||0.95 mL||4.74 mL||9.47 mL|
|10 mM||0.47 mL||2.37 mL||4.74 mL|
|50 mM||0.09 mL||0.47 mL||0.95 mL|
References are publications that support the products' biological activity.
If you know of a relevant reference for (R)-3-Carboxy-4-hydroxyphenylglycine, please let us know.
View Related Products by Product Action
Keywords: (R)-3-Carboxy-4-hydroxyphenylglycine, supplier, Ionotropic, glutamate, receptor, antagonists, Glutamate, Non-Selective, iGluR, Receptors, 3C4HPG, (R)-3C4HPG, Non-selective, Ionotropic, Glutamate, Non-selective, Ionotropic, Glutamate, Tocris Bioscience
Citations for (R)-3-Carboxy-4-hydroxyphenylglycine
Citations are publications that use Tocris products.
Currently there are no citations for (R)-3-Carboxy-4-hydroxyphenylglycine. Do you know of a great paper that uses (R)-3-Carboxy-4-hydroxyphenylglycine from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.